Evidence map›Paper›PMID 35433881›Full record

ArticleFrontiers in cardiovascular medicine2022

Impact of the COVID-19 Pandemic on ST-Elevation Myocardial Infarction Management in Hunan Province, China: A Multi-Center Observational Study.

Liang Tang, Zhao-Jun Wang, Xin-Qun Hu, Zhen-Fei Fang, Zhao-Fen Zheng, Jian-Ping Zeng, Lu-Ping Jiang, Fan Ouyang, Chang-Hui Liu, Gao-Feng Zeng and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 1 country.

Liang TangDepartment of Cardiology, The Second Xiangya Hospital of Central South University, Changsha, China.
Zhao-Jun WangDepartment of Cardiology, The Second Xiangya Hospital of Central South University, Changsha, China.
Xin-Qun HuDepartment of Cardiology, The Second Xiangya Hospital of Central South University, Changsha, China.
Zhen-Fei FangDepartment of Cardiology, The Second Xiangya Hospital of Central South University, Changsha, China.
Zhao-Fen ZhengHunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, China.
Jian-Ping ZengXiangtan Central Hospital, Xiangtan, China.
Lu-Ping JiangChangsha Central Hospital, Changsha, China.
Fan OuyangZhuzhou Central Hospital, Zhuzhou, China.
Chang-Hui LiuThe First Affiliated Hospital of University of South China, Hengyang, China.
Gao-Feng ZengThe Second Affiliated Hospital of University of South China, Hengyang, China.
Yong-Hong GuoDepartment of Geriatric, The Second Xiangya Hospital of Central South University, Changsha, China.
Sheng-Hua ZhouDepartment of Cardiology, The Second Xiangya Hospital of Central South University, Changsha, China.
Central South University · CNSecond Xiangya Hospital of Central South University · CNUniversity of South China · CNChangsha Central Hospital · CNHunan Provincial People's Hospital · CNXiangyang Central Hospital · CNZhuzhou Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: This study aimed to investigate the impact of the COVID-19 pandemic on ST-segment elevation myocardial infarction (STEMI) care in China. Methods: We conducted a multicenter, retrospective cohort study in Hunan province (adjacent to the epidemic center), China. Consecutive patients presenting with STEMI within 12 h of symptom onset and receiving primary percutaneous coronary intervention, pharmaco-invasive strategy and only thrombolytic treatment, were enrolled from January 23, 2020 to April 8, 2020 (COVID-19 era group). The same data were also collected for the equivalent period of 2019 (pre-COVID-19 era group). Results: A total of 610 patients with STEMI (COVID-19 era group Conclusion: During the COVID-19 pandemic outbreak in China, we observed a decline in the number of STEMI admissions and STEMI-related PCI procedures. However, the key quality indicators of STEMI care were not significantly affected. Restructuring health services during the COVID-19 pandemic has not significantly adversely influenced the in-hospital outcomes.

Indexed as

COVID-19outcomesprimary percutaneous coronary interventionST-segment elevation myocardial infarctionthrombolysis

Identifiers

PMID35433881
PMCPMC9008248
OpenAlexW4221066979

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.